This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone

Stephen R. Marder, MD; Robert Conley, MD; Larry Ereshefsky, PharmD, BCCP, FCCP; John M. Kane, MD; and Martin S. Turner, MB, BS

Published: November 1, 2003

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

The availability of a long-acting injectable atypicalantipsychotic may increase compliance with medication regimens in patients with schizophrenia. Currently,long-acting risperidone is the only such agent. It is nowavailable or approved in 33 countries, including Austria,Germany, Mexico, the Netherlands, New Zealand, and the United Kingdom.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Skeletal and Dental Fractures Associated With Electroconvulsive Therapy

Recent data suggest the risk of skeletal or dental fracture with ECT may be as low as...

Read More...